Your browser is no longer supported. Please, upgrade your browser.
Settings
BLCM Bellicum Pharmaceuticals, Inc. daily Stock Chart
BLCM [NASD]
Bellicum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-24.45 Insider Own0.30% Shs Outstand5.39M Perf Week-15.17%
Market Cap46.73M Forward P/E- EPS next Y-16.01 Insider Trans296.85% Shs Float4.98M Perf Month-53.88%
Income-110.70M PEG- EPS next Q-4.00 Inst Own31.10% Short Float7.58% Perf Quarter4.45%
Sales2.30M P/S20.32 EPS this Y15.80% Inst Trans-11.60% Short Ratio2.33 Perf Half Y-12.58%
Book/sh0.26 P/B33.35 EPS next Y27.80% ROA-97.70% Target Price43.50 Perf Year-74.27%
Cash/sh19.18 P/C0.45 EPS next 5Y- ROE-293.50% 52W Range7.21 - 41.40 Perf YTD-32.79%
Dividend- P/FCF- EPS past 5Y-9.60% ROI-91.40% 52W High-78.94% Beta1.67
Dividend %- Quick Ratio1.40 Sales past 5Y-10.40% Gross Margin86.20% 52W Low20.93% ATR1.85
Employees173 Current Ratio1.40 Sales Q/Q-66.70% Oper. Margin- RSI (14)36.58 Volatility8.28% 12.72%
OptionableYes Debt/Eq30.42 EPS Q/Q-23.50% Profit Margin- Rel Volume0.41 Prev Close8.67
ShortableYes LT Debt/Eq23.75 EarningsMar 10 AMC Payout- Avg Volume161.91K Price8.72
Recom1.50 SMA20-21.89% SMA50-33.34% SMA200-35.80% Volume61,355 Change0.58%
Apr-12-18Upgrade Wells Fargo Market Perform → Outperform
Apr-12-18Reiterated Cantor Fitzgerald Overweight $10 → $18
Jan-31-18Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17Initiated Wells Fargo Outperform
Dec-01-16Initiated Raymond James Outperform
Nov-30-16Initiated Ladenburg Thalmann Buy
Nov-02-16Initiated Cantor Fitzgerald Buy $32
Aug-09-16Upgrade Citigroup Neutral → Buy
Feb-25-16Initiated Citigroup Neutral $11
Sep-11-15Upgrade Guggenheim Neutral → Buy
Jul-24-15Initiated Citigroup Buy
Feb-07-20 09:42AM  Houston biotech firm raises millions; pharma co. enacts reverse stock split American City Business Journals -5.64%
Feb-05-20 12:45PM  Bellicum Announces Reverse Stock Split GlobeNewswire -17.81%
Feb-02-20 07:00AM  Activist Investors Made Moves in Trinity Industries, B. Riley, Axonics Barrons.com
Jan-31-20 04:05PM  Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -8.27%
11:15AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Bellicum Pharmaceuticals, Inc.- BLCM ACCESSWIRE
Jan-25-20 09:25AM  Here's What We Think About Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) CEO Pay Simply Wall St.
Jan-24-20 07:30AM  Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium GlobeNewswire -12.15%
Jan-22-20 09:33AM  Houston pharma co. to sell facility to MD Anderson Cancer Center American City Business Journals
Jan-21-20 07:30AM  Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson GlobeNewswire -6.11%
Jan-16-20 07:30AM  Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium GlobeNewswire +23.53%
Dec-13-19 02:45PM  Hedge Funds Are Betting On Bellicum Pharmaceuticals Inc (BLCM) Insider Monkey -6.66%
Dec-11-19 07:30AM  Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson GlobeNewswire +40.72%
Dec-10-19 06:42AM  Is Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) A Volatile Stock? Simply Wall St.
Nov-22-19 10:50PM  BELLICUM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Bellicum Pharmaceuticals, Inc. - BLCM Business Wire
Nov-17-19 07:14AM  Edited Transcript of BLCM earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-08-19 07:00AM  Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire +5.46%
Nov-06-19 07:15PM  Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:15PM  Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update GlobeNewswire
Oct-31-19 04:05PM  Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019 GlobeNewswire -7.37%
Oct-30-19 07:30AM  Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire -8.29%
Oct-29-19 10:33AM  Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline Zacks +9.77%
Oct-26-19 08:57AM  Introducing Bellicum Pharmaceuticals (NASDAQ:BLCM), The Stock That Tanked 95% Simply Wall St.
Sep-30-19 04:07PM  Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-23-19 10:54AM  Top Ranked Momentum Stocks to Buy for September 23rd Zacks
Sep-03-19 02:53PM  Do Insiders Own Lots Of Shares In Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)? Simply Wall St.
Aug-30-19 04:08PM  Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-28-19 04:05PM  Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September GlobeNewswire
Aug-21-19 04:05PM  Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement GlobeNewswire
Aug-20-19 03:47PM  Houston pharma co. raises $69.6M through public offering, private placement American City Business Journals
Aug-16-19 10:56AM  CORRECTING and REPLACING -Bellicum Pharmaceuticals, Inc. GlobeNewswire
08:30AM  Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement GlobeNewswire
Aug-15-19 05:37PM  Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement GlobeNewswire
Aug-05-19 06:15PM  Bellicum Pharmaceuticals (BLCM) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.80%
04:15PM  Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update GlobeNewswire
Jul-30-19 10:38AM  Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-19-19 07:32AM  Should You Worry About Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) CEO Pay? Simply Wall St. -7.51%
Jul-08-19 08:00AM  Bellicum Pharmaceuticals Announces Rivo-cel Achieves Primary Endpoint in Pediatric Registrational Trial GlobeNewswire
Jun-13-19 11:53AM  Does Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Have A High Beta? Simply Wall St.
Jun-01-19 09:00AM  Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting GlobeNewswire
May-31-19 07:00PM  Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and Encourages Bellicum Investors to Contact the Firm GlobeNewswire
04:14PM  Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-29-19 04:05PM  Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference GlobeNewswire
May-20-19 08:38AM  (BLCM) Alert: Johnson Fistel, LLP Announces Investigation of Bellicum Pharmaceuticals, Inc.; Long Term Investors Encouraged to Contact Firm PR Newswire -7.51%
May-15-19 04:05PM  Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting GlobeNewswire
May-07-19 10:30AM  Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
08:55AM  Bellicum Pharmaceuticals (BLCM) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:30AM  Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update GlobeNewswire
Mar-27-19 07:30AM  Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit GlobeNewswire
Mar-15-19 03:43PM  Edited Transcript of BLCM earnings conference call or presentation 12-Mar-19 9:00pm GMT Thomson Reuters StreetEvents
Mar-12-19 04:01PM  Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018 GlobeNewswire
07:35AM  Bellicum Pharmaceuticals Q4 Earnings Preview Benzinga
Mar-05-19 07:00AM  Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call and Webcast on Tuesday, March 12, 2019 GlobeNewswire
Jan-30-19 07:30AM  Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-22-19 12:26PM  How Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Could Add Value To Your Portfolio Simply Wall St.
08:40AM  Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher Zacks
Dec-27-18 09:47AM  Bellicum Pharmaceuticals Enters Oversold Territory Zacks +8.77%
Dec-24-18 10:08AM  Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA Zacks
Dec-20-18 07:00AM  Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors GlobeNewswire
Dec-14-18 07:00AM  Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO GlobeNewswire
Dec-13-18 07:00AM  Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer GlobeNewswire
Dec-11-18 09:22AM  Novan Announces Top-Line Data From Mid-Stage Molluscum Study Zacks
Dec-02-18 10:30AM  Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel GlobeNewswire
Dec-01-18 02:00PM  Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant GlobeNewswire
12:00PM  Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018 GlobeNewswire
Nov-28-18 08:30AM  Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-27-18 07:00AM  Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3 GlobeNewswire
Nov-22-18 11:53AM  Before You Buy Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), Consider Its Volatility Simply Wall St.
Nov-07-18 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-06-18 06:00PM  Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-18 09:01AM  Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting GlobeNewswire +8.35%
Oct-17-18 08:30AM  Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-23-18 08:15AM  Factors of Influence in 2018, Key Indicators and Opportunity within Qurate Retail Group, Bellicum Pharmaceuticals, CannTrust, Iconix Brand Group, Maxwell Technologies, and AZUL SA New Research Emphasizes Economic Growth GlobeNewswire
Aug-20-18 11:45PM  Edited Transcript of BLCM earnings conference call or presentation 7-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-07-18 07:50PM  Bellicum Pharmaceuticals (BLCM) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results GlobeNewswire
03:00PM  Bellicum Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-06-18 07:00AM  Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501 GlobeNewswire
Aug-04-18 01:04PM  Here's Why Bellicum Pharmaceuticals Lost 13.8% in July Motley Fool
Jul-31-18 07:00AM  Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 GlobeNewswire
Jul-24-18 07:30AM  Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks ACCESSWIRE
Jul-16-18 04:25PM  Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer GlobeNewswire
Jun-25-18 07:15AM  Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks ACCESSWIRE
Jun-15-18 07:45AM  Analysis: Positioning to Benefit within Uranium Energy, Bellicum Pharmaceuticals, Tutor Perini, Maiden, Hill-Rom, and BioDelivery Sciences International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-12-18 08:20AM  Today's Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Sangamo Therapeutics ACCESSWIRE
May-30-18 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-29-18 07:00AM  Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel GlobeNewswire
May-17-18 09:20AM  Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association GlobeNewswire
May-15-18 07:00AM  Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
May-10-18 08:20AM  Todays Research Reports on Stocks to Watch: OPKO Health and Bellicum Pharmaceuticals ACCESSWIRE
May-09-18 01:57PM  Here's Why Bellicum Pharmaceuticals Is Jumping Higher Today Motley Fool +15.60%
May-08-18 04:01PM  Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-20-18 04:05PM  Bellicum Pharmaceuticals Announces Closing of Public Offering GlobeNewswire
Apr-17-18 06:26PM  Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -12.60%
02:33PM  Here's Why Bellicum Pharmaceuticals Dropped as Much as 14.6% Today Motley Fool
Apr-16-18 04:42PM  Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-12-18 09:47AM  Is Bellicum Pharmaceuticals Stock Now a Strong Buy? Motley Fool +20.29%
08:30AM  Todays Research Reports on Trending Tickers: Argos Therapeutics and Bellicum Pharmaceuticals ACCESSWIRE
07:51AM  What Do Analysts Think About Bellicum Pharmaceuticals Incs (NASDAQ:BLCM) Long Term Outlook? Simply Wall St.
Apr-11-18 04:17PM  Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501 GlobeNewswire
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesu, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fair Richard A.President and CEOSep 10Buy1.2540,00050,00066,561Sep 11 07:01 PM
Ward ShaneSr. VP and General CounselAug 29Buy1.238,0009,82218,294Aug 30 04:01 PM
Fair Richard A.President and CEOAug 21Buy0.9920,00019,78026,561Aug 23 04:03 PM